Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Young Jonathan						2. Issuer Name and Ticker or Trading Symbol Akero Therapeutics, Inc. [AKRO]								5. Relationship of Reporting Pe (Check all applicable) Director			10%	Owner
(Last) (First) (Middle) C/O AKERO THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 08/01/2024									Officer (give title Other (specification) Chief Operating Officer				w)
601 GATEWAY BOULEVARD, SUITE 350						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) SOUTH SAN FRANCISCO CA 94941				Form filed by One Reporting Person Form filed by More than One Reporting Person														
				Rule 10b5-1(c) Transaction Indication														
(City) (State) (Zip)				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - Non-l	Derivat	tive	Secur	ities	Acq	uire	ed, D	isposed (of, or	Benefici	ally Ov	vned			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				2A. Deemed Execution Date, if any (Month/Day/Year)			C	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 at			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership	
								C	ode	v	Amount	(A) or (D)	Price	Trans	rted action(s) 3 and 4)	(Instr.	4)	(Instr. 4)
Common Stock 08/01/202-					1			S	S ⁽¹⁾		3,031	D	\$26.44(2	2	43,823	I		
Common Stock 08/01/2024								S	g ⁽¹⁾		1,969	D	\$27.23(3	3 ⁽³⁾ 241,854		I)	
Common Stock														2	0,000		I	By EA Irrevocable Trust ⁽⁴⁾
Common Stock														2	0,000	000		By CM Irrevocable Trust ⁽⁴⁾
Common Stock														2	20,000		I	By JL Irrevocable Trust ⁽⁴⁾
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any			Transaction of Code (Instr. 8) Se Ad (A Di of (Ir		5. Nun of Deriva Securi Acquii (A) or Dispos of (D) (Instr. and 5)	tive ties red sed	Expi	iration	ercisable and Date y/Year)	Amo Secu Unde Deriv Secu	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of 9. Numl derivati Securiti Benefic Owned Followi Reporte Transac (Instr. 4	ative Own ities Forr ficially Dire d or In wing (I) (In rted action(s)		Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	e rcisabl	Expiration e Date	n Title	Amount or Number of Shares					

Explanation of Responses:

- 1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 27, 2023, previously adopted by the Reporting Person.
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$26.19 to \$26.81, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2).
- 3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$26.91 to \$27.88, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3).
- 4. These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

/s/ Jonathan Young, Attorney-

08/02/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.